NMRA - Neumora Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NMRA is currently covered by 5 analysts with an average price target of $13.25. This is a potential upside of $11.64 (722.98%) from yesterday's end of day stock price of $1.61.

Neumora Therapeutics's activity chart (see below) currently has 0 price targets and 21 ratings on display. The stock rating distribution of NMRA is 95.24% BUY and 4.76% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 10% with an average time for these price targets to be met of 24.4 days.

Highest price target for NMRA is $29, Lowest price target is $7, average price target is $17.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 14-Feb-2025. First documented stock forecast 10-Oct-2023.

Best performing analysts who are covering NMRA - Neumora Therapeutics:

Ami Fadia Douglas Tsao Brian Abrahams Tessa Romero Geoff Meacham

Currently out of the existing stock ratings of NMRA, 20 are a BUY (95.24%), 1 are a HOLD (4.76%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

6 months 7 days ago
(14-Feb-2025)

0/3 (0%)

$19.13 (175.99%)

Buy

$7

$5.37 (329.45%)

$18

7 months 15 days ago
(06-Jan-2025)

1/2 (50%)

$4.52 (182.26%)

122

Buy

$23

7 months 19 days ago
(02-Jan-2025)

0/5 (0%)

$12.22 (113.36%)

Buy

$29

$27.37 (1679.14%)

$29

8 months 30 days ago
(22-Nov-2024)

0/4 (0%)

$19.26 (197.74%)

Hold

$15

$13.37 (820.25%)

$22

9 months 16 days ago
(05-Nov-2024)

0/4 (0%)

$3.09 (25.94%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NMRA (Neumora Therapeutics) average time for price targets to be met?

On average it took 24.4 days on average for the stock forecasts to be realized with a an average price target met ratio 10

Which analyst has the current highest performing score on NMRA (Neumora Therapeutics) with a proven track record?

AMI FADIA

Which analyst has the current lower performing score on NMRA (Neumora Therapeutics) with a proven track record?

GEOFF MEACHAM

Which analyst has the most public recommendations on NMRA (Neumora Therapeutics)?

Ami Fadia works at NEEDHAM and has 7 price targets and 5 ratings on NMRA

Which analyst is the currently most bullish on NMRA (Neumora Therapeutics)?

Brian Abrahams with highest potential upside - $27.37

Which analyst is the currently most reserved on NMRA (Neumora Therapeutics)?

Ami Fadia with lowest potential downside - -$0

Neumora Therapeutics in the News

Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215

Earnings Call Insights: Neumora Therapeutics (NMRA) Q2 2025 MANAGEMENT VIEW * Paul L. Berns, Chief Executive Officer, stated that Neumora “prioritized obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibitor.” He outlined, “We expect to have up to 6 clinical data readouts in patients over the next 18 months, and I’m excited...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?